According to Arrowhead Pharmaceuticals 's latest financial reports the company's current revenue (TTM) is $0.18 B. In 2022 the company made a revenue of $0.27 B an increase over the years 2021 revenue that were of $0.14 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.18 B | -34.71% |
2022 | $0.27 B | 92.72% |
2021 | $0.14 B | 80.89% |
2020 | $79.84 M | -51.2% |
2019 | $0.16 B | 245.93% |
2018 | $47.29 M | 54.79% |
2017 | $30.55 M | 581.95% |
2016 | $4.48 M | 1656.89% |
2015 | $0.25 M | -15.56% |
2014 | $0.3 M | 72.57% |
2013 | $0.17 M | -37.93% |
2012 | $0.28 M | 1076.78% |
2011 | $0.02 M | -99.46% |
2010 | $4.46 M | 38.8% |
2009 | $3.21 M | 100.33% |
2008 | $1.6 M | |
2006 | $0.35 M | -50.39% |
2005 | $0.71 M | |
2002 | $0 M | -54.56% |
2001 | $0 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $93.02 B | 51,084.11% | ๐บ๐ธ USA |
Moderna
MRNA | $6.75 B | 3,616.30% | ๐บ๐ธ USA |
Ligand Pharmaceuticals LGND | $0.13 B | -27.75% | ๐บ๐ธ USA |
Dicerna Pharmaceuticals DRNA | $0.19 B | 6.11% | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | $1.82 B | 905.99% | ๐บ๐ธ USA |
Inovio Pharmaceuticals INO | $0.83 M | -99.54% | ๐บ๐ธ USA |